OMBITASVIR/PARITAPREVIR/RITONAVIR PLUS DASABUVIR TREATMENT EXPERIENCE IN HCV PATIENTS

Bayan K., ÇELEN M. K., DAL T., AYAZ C., TEKİN R., Akdemir İ., ...Daha Fazla

ACTA MEDICA MEDITERRANEA, cilt.34, sa.1, ss.71-75, 2018 (SCI-Expanded, Scopus)

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 34 Sayı: 1
  • Basım Tarihi: 2018
  • Doi Numarası: 10.19193/0393-6384_2018_1_12
  • Dergi Adı: ACTA MEDICA MEDITERRANEA
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.71-75
  • Anahtar Kelimeler: Hepatitis C, treatment, genotype, C VIRUS GENOTYPES, CHRONIC HEPATITIS-C, INFECTION, ABT-450/R-OMBITASVIR, RIBAVIRIN, TURKEY, EFFICACY, PROVINCE
  • Ankara Üniversitesi Adresli: Hayır

Özet

Introduction: Achieving sustained virologic response (SVR) is critical in HCV patients. In current study, we aimed to investigate the efficacy and safety of DAA (OBV/PTV/r + DSV +/- RBV) treatment regimen in patients with HCV.